Biology subjects

Shankaran, D.

Publications and source records attributed to Shankaran, D..

4 recordsLinked to original sources

bioRxiv2025

Macrophage Cholesterol Homeostasis Underpins the role of Sertraline as an Adjunctive Agent in Tuberculosis Therapy.

Cellular metabolism plays a deterministic role in the macrophage responses to intracellular pathogens such as Mycobacterium tuberculosis (Mtb) and infection control. Here, we demonstrate that the significant rewiring of the macrophage cholesterol metabolism by sertraline (SRT), an FDA-approved antidepressant, effectively enhances bacterial control. SRT, by virtue of its potent cationic amphiphilicity leads to the accumulation of lysosomal cholesterol in macrophages and activating the transcription factor SREBP2 and enhancing cholesterol biosynthesis. By specific gene silencing and biochemical inhibition assays, we further demonstrate that this metabolic reprogramming promotes lysosomal membrane permeabilization, mitochondrial reactive oxygen species (ROS) generation, heightened IL-1{beta} release, collectively enhancing macrophage bactericidal activity. Our results thus highlight a previously underappreciated link between cholesterol homeostasis and inflammasome activation, which contributes to improved Mtb clearance in the presence of adjunctive sertraline therapy. Statement of significanceTuberculosis remains a leading cause of global mortality, and treatment success is limited due to a long treatment regimen. This study identifies macrophage cholesterol homeostasis as a central pathway to enhance anti-tubercular therapy. We show that Sertraline, an FDA-approved antidepressant, a cationic amphiphilic drug (CAD), reprograms cholesterol trafficking through NPC1 inhibition. This drives the consequential processing of the master regulator SREBP2, accompanied by lysosomal membrane permeabilization. Collectively, these lead to mitochondrial ROS production and activation of NLRP3 signalling, boosting inflammasome-mediated bacterial clearance. By establishing cholesterol sequestration as the mechanistic basis of host-directed activity of sertraline and distinguishing it from ineffective CADs, our work provides a mechanistic framework for developing cholesterol-modulating host-directed adjuncts to improve TB treatment outcomes. Graphical abstract: SRT induced lysosomal cholesterol accumulation results in enhanced bacterial control via inflammasome activation O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=101 SRC="FIGDIR/small/665474v3_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@1019b4dorg.highwire.dtl.DTLVardef@7b0ae8org.highwire.dtl.DTLVardef@9297eorg.highwire.dtl.DTLVardef@1832bef_HPS_FORMAT_FIGEXP M_FIG C_FIG

immunology↗

bioRxiv2021

The mitochondrial gene CMPK2 functions as a rheostat for macrophage homeostasis in inflammation

In addition to their role in cellular energy production, mitochondria are increasingly recognized as regulators of the innate immune response of phagocytes. Here, we demonstrate that altering expression levels of the mitochondria associated enzyme, cytidine monophosphate kinase 2 (CMPK2), disrupts mitochondrial physiology and significantly de-regulates the resting immune homeostasis of macrophages. Both CMPK2 silenced as well as constitutively over expressing macrophage lines portray mitochondrial stress with marked depolarization of their membrane potential, enhanced ROS and disturbed architecture culminating in the enhanced expression of the pro-inflammatory genes-IL1{beta}, TNF and IL8. Interestingly, the long-term modulation of CMPK2 expression resulted in an increased glycolytic flux of macrophages akin to the altered physiological state of activated M1 macrophages. While infection induced inflammation for restricting pathogens is regulated, our observation of a total dysregulation of basal inflammation by bidirectional alteration of CMPK2 expression, only highlights a critical role of this gene in mitochondria mediated control of inflammation.

immunology↗

bioRxiv2020

The antidepressant sertraline provides a novel host directed therapy module for augmenting TB therapy

A prolonged therapy, primarily responsible for development of drug resistance by Mycobacterium tuberculosis (Mtb), obligates any new TB regimen to not only reduce treatment duration but also escape pathogen resistance mechanisms. With the aim of harnessing the host response in providing support to existing regimens, we used sertraline (SRT) to stunt the pro-pathogenic type I IFN response of macrophages to infection. While SRT alone could only arrest bacterial growth, it effectively escalated the bactericidal activities of Isoniazid (H) and Rifampicin (R) in macrophages. This strengthening of antibiotic potencies by SRT was more evident in conditions of ineffective control by these frontline TB drug, against tolerant strains or dormant Mtb. SRT, could significantly combine with standard TB drugs to enhance early pathogen clearance from tissues of mice infected with either drug sensitive/ tolerant strains of Mtb. Further, we demonstrate an enhanced protection in acute TB infection of the highly susceptible C3HeB/FeJ mice with the combination therapy signifying the use of SRT as a potent adjunct to standard TB therapeutic regimens against bacterial populations of diverse physiology. This study advocates a novel host directed adjunct therapy regimen for TB with a clinically approved anti-depressant to achieve quicker and greater control of infection.

immunology↗

bioRxiv2019

Modern clinical Mtb strains leverage the type I IFN pathway for a pro-inflammatory response in the host

Host phagocytes respond to infections by innate defense mechanisms through metabolic shuffling in order to restrict the invading pathogen. However, this very plasticity of the host provides an ideal platform for pathogen mediated manipulation. By employing the macrophage model of Mtb infection, we identify an important strategy employed by modern clinical lineages in regulating the host immune-metabolism axis. The potent ability of these strains to specifically elicit a strong and early macrophage type I IFN response (in contrast to the protracted response to ancient Mtb), was dependent on an increased ability to localize in acidified phagosomes; this higher transit via acidified compartments is important for stimulation of the DNA dependent signaling in infected macrophages. The augmented IFN signaling provided a positive regulatory loop for enhanced expression of the cellular oxysterol-CH25H which in turn facilitated higher levels of IL6 in macrophages infected with the modern Mtb strains. Requirement of type I IFN signaling in mycobacterial intracellular growth highlights another unique ability of Mtb to manipulate host cell physiology and proinflammatory responses.\n\nSignificance StatementCo-evolution with humans has enabled the development of novel adaptive mechanisms for survival in host specific environments in the human TB pathogen-Mtb. We present one such mechanism of modern Mtb strains harnessing the type I IFN immune axis to regulate the host pro-inflammatory response. Our results highlight the use of host intracellular endosomal transit as a mechanism by these strains to ensure a strong type I IFN response in macrophages. We also demonstrate the ability of Mtb to regulate macrophage cholesterol metabolism in order to fine tune the host innate responses. These findings lay the foundation of the future development of a host axis directed intervention strategy against this pathogen.

immunology↗